

1 **Aggressive Periodontitis with Neutropenia Caused by *MMD2* Mutation**

2

3 Noriyoshi Mizuno, DDS, PhD^{1*}, Hiroyuki Morino, MD, PhD², Keichiro Mihara, MD, PhD³,
4 Tomoyuki Iwata, DDS, PhD¹, Yoshinori Ohno, PhD⁴, Shinji Matsuda, DDS, PhD¹, Kazuhisa
5 Ouhara, DDS, PhD¹, Mikihito Kajiya, DDS, PhD¹, Kyoko Suzuki-Takedachi, PhD⁴, Yusuke
6 Sotomaru, PhD⁵, Katsuhiko Takeda, DDS, PhD⁶, Shinya Sasaki, DDS, PhD¹, Ai Okanobu,
7 DDS, PhD¹, Tetsushi Sakuma, PhD⁷, Takashi Yamamoto, PhD⁷, Yukiko Matsuda, PhD²,
8 Ryouzuke Ohsawa, PhD², Tsuyoshi Fujita, DDS, PhD¹, Hideki Shiba, DDS, PhD⁶, Hideshi
9 Kawakami, MD, PhD^{2*}, Hidemi Kurihara, DDS, PhD¹

10

11 ¹Department of Periodontal Medicine, Graduate School of Biomedical and Health Sciences,
12 Hiroshima University, 1-2-3, Kasumi, Minami-ku, Hiroshima, 734-8553, Japan

13 ²Department of Epidemiology, Research Institute for Radiation Biology and Medicine,
14 Hiroshima University, Hiroshima, 1-2-3, Kasumi, Minami-ku, Hiroshima, 734-8553, Japan

15 ³Department of Hematology and Oncology, Research Institute for Radiation Biology and
16 Medicine, Hiroshima University, Hiroshima, 1-2-3, Kasumi, Minami-ku, Hiroshima,
17 734-8553, Japan

18 ⁴Department of Stem Cell Biology, Research Institute for Radiation Biology and Medicine,
19 Hiroshima University, Hiroshima, 1-2-3, Kasumi, Minami-ku, Hiroshima, 734-8553, Japan

20 ⁵Natural Science Center for Basic Research and Development, Hiroshima University,
21 Hiroshima, 1-2-3, Kasumi, Minami-ku, Hiroshima, 734-8553, Japan

22 ⁶Department of Biological Endodontics, Graduate School of Biomedical and Health Sciences,
23 Hiroshima University, 1-2-3, Kasumi, Minami-ku, Hiroshima, 734-8553, Japan

24 ⁷Department of Mathematical and Life Sciences, Graduate School of Science, Hiroshima
25 University, 1-3-1 Kagamiyama, Higashi-Hiroshima 739-8526, Japan

26

27 ***Corresponding authors**

28 Noriyoshi Mizuno, DDS, PhD

29 1-2-3 Kasumi, Minami-ku, Hiroshima, 734-8553 Japan

30 Telephone number: +81-82-257-5663

31 Fax number: +81-82-257-5664

32 Email address: mizuno@hiroshima-u.ac.jp

33

34 Hideshi Kawakami, MD, PhD.

35 1-2-3 Kasumi, Minami-ku, Hiroshima, Japan, 734-8553

36 Telephone number: +81-82-257-5850

37 Fax number: +81-82-257-5848

38 Email address: hkawakam@hiroshima-u.ac.jp

39

40

41 **Abstract**

42 Aggressive periodontitis causes rapid periodontal tissue destruction and is a disease that
43 occurs at a young age and runs in the patient's family. Here, we revealed a heterozygous
44 A116V missense mutation in the gene encoding monocyte to macrophage differentiation
45 associated 2 (MMD2) protein in a Japanese family with aggressive periodontitis and
46 neutropenia. Analyses of patients' peripheral blood revealed a low number of neutrophils but
47 abundant quantity of CD34⁺ hematopoietic stem and progenitor cells (HSPCs). Moreover,
48 mutant *Mmd2* mice showed severe alveolar bone loss and neutropenia. In patients and mutant
49 *Mmd2* mice, differentiation of HSPCs into granulocytes was also impeded, and their
50 granulocytes were functionally impaired. Taken together, A116V mutation in *MMD2* gene
51 induced mild neutropenia and slightly limited the immune defense response. Our studies
52 suggested that aggressive periodontitis in association with A116V *MMD2* mutation
53 constitutes a new immune system defect that belongs to the same spectrum of severe
54 congenital neutropenia.

55 **Introduction**

56 Aggressive periodontitis, formerly called early onset periodontitis or juvenile
57 periodontitis, has an early onset and runs in the patient's family (Nishimura et al., 1990;
58 Trevilatto et al., 2002; Llorente, 2006). This disease is characterized by the loss of many teeth
59 due to rapid periodontal tissue destruction, with no evident symptoms in other tissues. The
60 prevalence of this disease is 0.1% -0.2% in Caucasians, 0.4% -1.0% in Asians, and 1.0% -
61 3.0% in African Americans (Albandar, 2000). It has been indicated that neutrophil
62 abnormalities lead to the onset of the disease because they allow for bacterial growth, which
63 follows severe periodontal destruction. Especially, abnormalities in neutrophil chemotaxis
64 and superoxide production have been reported as the causes, but the detailed mechanism has
65 not been elucidated (Van Dyke, 1980; Van Dyke, 1985; Shapira, 1991). The current
66 treatment of this disease is mainly symptomatic, but some patients have a poor outcome even
67 after treatment. The purpose of this study was to identify the causative gene of aggressive
68 periodontitis and analyze whether the onset of this disease was associated with neutrophil
69 abnormalities in order to elucidate its pathogenesis.

70 Here, we reported the identification of a missense mutation in the *monocyte to*
71 *macrophage differentiation associated 2 (MMD2)* gene, in a Japanese family with autosomal
72 dominant aggressive periodontitis. Furthermore, we provided some insight about the
73 involvement of MMD2 protein in neutrophil differentiation.

74

75 **Results**

76 **Characteristic findings in patients**

77 In this study, we focused on a Japanese family with dominantly inherited aggressive
78 periodontitis. The pedigree of this family is shown in Fig. 1A. The proband (III-4) developed
79 gingival swelling and pain in his late teens but was admitted at our hospital at the age of 24.
80 His upper left molar was difficult to preserve and thus it was extracted. Deep periodontal
81 pockets were found in other teeth. The proband's two brothers (III-2 and III-3) also showed
82 the same symptoms in their late teens. In a further interview, it was noted that proband's
83 deceased grandfather (I-1), deceased father (II-4), and uncle (II-6) also had aggressive
84 periodontitis, and the deceased I-1 and II-4 individuals used dentures from a young age.
85 Interestingly, the patients were systemically healthy, except they had severe periodontitis with
86 alveolar bone loss. CT images of subjects III-2 and III-4 at the age of 45 and 40, respectively,
87 exhibited a damaged tooth with half to one-third alveolar bone resorption around the tooth
88 root, compared with that of the healthy subject, even though the patients had received
89 professional dental treatment from teen-age to their 40s (Fig. 1B). On the other hand, the
90 examination of oral cavities of II-1, II-5, II-9, and III-5 revealed that they were healthy and
91 not suffering from periodontitis. Data on complete blood count (III-2, 3, and 4) are given in
92 Table S1. Red blood cell and platelet counts were normal; meanwhile, the white blood cell
93 counts were below the lower normal limit. The ratios of neutrophils in the white blood cells
94 were also relatively lower, the numbers were approximately 883-970 / μ l. Flow cytometric
95 analysis revealed adequate amounts of CD34⁺ hematopoietic stem and progenitor cells
96 (HSPCs) (III-2; 2.6 ± 1.07 %, III-4; 1.74 ± 0.53 %) in the patients' bone marrow (Ueda et al.,
97 2001). Even though the numbers of CD34⁺ HSPCs in the bone marrows of the two patients
98 were normal, their differentiation to granulocytes were impeded (Fig. 2A). We observed that

99 apoptotic cells were higher in number in these patients' setting (data not shown). Interestingly,
100 detailed flow cytometric analysis indicated many CD34⁺ HSPCs in patients' peripheral blood
101 (CD34⁺ HSPCs/ CD45⁺ cells accounted for 3.3 % in patient III-2, 1.7 % in patient III-4, and
102 0.08 % in age-matched healthy subject) (Fig. 2B), which is only transiently seen when
103 peripheral blood is mobilized by granulocyte colony stimulating factor (G-CSF) and
104 high-dose of chemotherapy or plerixafor. However, this condition seen in patients' peripheral
105 blood was persistent rather than transient. Moreover, neutrophil chemotaxis, assessed by
106 stimulation with N-formyl-methionyl-leucyl-phenylalanine (fMLP), was also decreased in the
107 analyzed patients when compared to that of age-matched healthy subjects (Fig. 2C).

108 **Identification of the *MMD2* mutation**

109 Our aim was to identify the causative gene mutation in this family. By the linkage
110 analysis, two regions with logarithm of odds (LOD) score of 1.8047 and 1.8058 were
111 obtained in chromosomes 3 and 7, respectively (Fig. 3A and B). As a result of exome
112 sequencing, seven heterozygous variants were identified (Table S2). We performed
113 segregation analysis of the variants in the eight subjects from the family. The variant c.347
114 C>T, p. A116V in *MMD2* was observed only in affected subjects (II-6, III-2, III-3, and III-4)
115 but not in unaffected subjects (II-1, II-5, II-9, and III-5). Based on the linkage analysis, this
116 *MMD2* variant was present in the high LOD region; therefore, we concluded that *MMD2*
117 variant was most likely associated with periodontitis. This variant was further confirmed by
118 Sanger sequencing (Fig. 3C). The nucleotide and amino acid sequences of the mutated region
119 were completely conserved among vertebrates (Fig. 3D). This variant had a Combined
120 Annotation Dependent Depletion (CADD) score of 28.9 and was pathogenic (>15) (Table S3).
121 This *MMD2* variant was neither found in other Japanese 102 patients with severe
122 periodontitis nor in 275 healthy subjects. Additionally, this mutation has not been detected in

123 the Integrative Japanese Genome Variation Database (database for 7,108 allele number),
124 Human Genetic Variation Database (database for 2,416 allele number), or East Asian
125 Database (database for 19,530 allele number, allele frequency; 0.000), but it was found in 8
126 alleles in European (database for 128,298, allele frequency; 0.00006235) and in 2 alleles in
127 Latino populations (database for 35,374, allele frequency; 0.00005654) by Genome
128 Aggregation Database. Therefore, this mutation is rare, but it exists.

129 **Cellular localization of MMD2 protein**

130 Immunohistochemical studies were performed to examine the subcellular localization
131 of MMD2 protein. Although human MMD2 protein localization is restricted to the Golgi
132 apparatus when overexpressed (Jin et al., 2012), in our study we observed its presence in the
133 Golgi apparatus even in a steady state, colocalizing with the Golgi marker Golgin-97 (Fig.
134 3E) in neutrophil-like HL-60 cells. MMD2 is known as an integral membrane protein with its
135 N-terminus facing the cytosol and seven transmembrane (TM) regions (Tang et al., 2005).
136 Specifically, the *MMD2* A116V mutation was localized in TM3 (Fig. 3F).

137 **Mouse model**

138 The exact function of MMD2 has not been elucidated. Therefore, we created a
139 knock-in mouse model (*Mmd2*^{A117V/A117V} mice) carrying an amino acid substitution in *Mmd2*,
140 which corresponded to the A116V mutation observed in the *MMD2* human gene. Platinum
141 TALENs were designed to generate a double-stranded break near the targeted nucleotide
142 c.347C>T in exon 4 of *Mmd2* gene (Fig. 4A). The target template for homologous
143 recombination was constructed (Fig. 4B). The 25 bp oligonucleotide contained 4 single
144 nucleotide differences, including the nonsynonymous C>T substitution encoding the mouse
145 A117V mutation and a synonymous change that introduced a PstI site (Fig. 4C). The genome
146 editing of the targeted nucleotide mutations resulted in five random deletions and one indel,

147 as the 5 bp, 7 bp, and 11 bp deletions produced frameshift mutations. We used the mice with
148 7 bp deletions in *Mmd2* as the knock-out mice (*Mmd2*^{-/-} mice) (Fig. 4D and Fig. 4E).

149 ***Mmd2* mutation causes severe alveolar bone loss**

150 Whether severe periodontitis was induced in *Mmd2*^{A117V/A117V} and *Mmd2*^{-/-} mice was
151 investigated using the common ligature-induced periodontitis model (Abe, 2013). Alveolar
152 bone was only markedly absorbed at the time of inflammation in both *Mmd2*^{A117V/A117V} and
153 *Mmd2*^{-/-} mice, compared to wild-type (*Mmd2*^{+/+}) mice (Fig. 5A). The degree of alveolar bone
154 loss was statistically higher in *Mmd2*^{A117V/A117V}, *Mmd2*^{A117V/+}, and *Mmd2*^{-/-} mice, than in
155 *Mmd2*^{+/+} mice (p = 0.01) (Fig. 5B).

156 ***Mmd2* mutation causes abnormal differentiation of granulocytes**

157 We also examined whether the differentiation of HSPCs to granulocytes was prevented
158 in *Mmd2*^{A117V/A117V} and *Mmd2*^{-/-} mice. Blood parameters were analyzed to determine whether
159 *Mmd2*^{A117V/A117V} and *Mmd2*^{-/-} mice showed mild neutropenia. The number of red blood cells
160 and platelets, as well as the levels of hemoglobin did not change in *Mmd2*^{A117V/A117V} and
161 *Mmd2*^{-/-} mice (Table S4). However, the ratios of granulocytes in these two mice were lower
162 than that in *Mmd2*^{+/+} mice (*Mmd2*^{A117V/A117V} mice: p = 0.006 and *Mmd2*^{-/-} mice: p = 0.03) (Fig.
163 6A). To test whether this decrease in granulocyte numbers was associated with the
164 differentiation ability of HSPCs, we examined the colony-forming ability of bone marrow
165 cells in *Mmd2*^{A117V/A117V} and *Mmd2*^{-/-} mice. Stimulation with interleukin (IL)-3, granulocyte
166 and macrophage colony stimulating factor (GM-CSF), and macrophage colony stimulating
167 factor (M-CSF) indicated an abundance of early myeloid or monocytic precursor cells in
168 *Mmd2*^{A117V/A117V} and *Mmd2*^{-/-} bone marrow cells. In contrast, stimulation of *Mmd2*^{A117V/A117V}
169 and *Mmd2*^{-/-} bone marrow cells with G-CSF resulted in fewer colonies than those obtained
170 with *Mmd2*^{+/+} bone marrow cells (p < 0.001) (Fig. 6B). This suggested that the number of

171 granulocytic precursor cells decreased in the bone marrow of *Mmd2*^{A117V/A117V} and *Mmd2*^{-/-}
172 mice. Moreover, neutrophil chemotaxis, assessed by stimulation with fMLP, also decreased in
173 *Mmd2*^{A117V/A117V} and *Mmd2*^{-/-} mice compared with that in *Mmd2*^{+/+} mice (Fig. 6C).

174 Thus, severe alveolar bone loss and abnormal differentiation of granulocytes in both
175 *Mmd2*^{A117V/A117V} and *Mmd2*^{-/-} mice strongly suggested that *MMD2* mutation in our patients
176 could be the cause of aggressive periodontitis with neutropenia.

177

178 **Discussion**

179 Study of subjects from a Japanese family indicated that *MMD2* gene was involved in
180 autosomal dominant aggressive periodontitis. Our findings strongly suggested that *MMD2*
181 gene was involved in the differentiation and function of neutrophils and that the presence of
182 mutations in *MMD2* reduced the protective response to chronic bacterial infection. In patients
183 with mutations in *MMD2* gene, HSPCs cannot differentiate into granulocytes and thus they
184 may leak from bone marrow into peripheral blood. *MMD2* mutation was also associated with
185 a decrease in neutrophil numbers and dysfunction, leading to severe periodontal destruction.

186 Neutrophil abnormalities are also found in severe congenital neutropenia (SCN). SCN,
187 which poses a severe risk of infection since neonatal age, originates as a result of mutations
188 in one of several different genes (Lanciotti et al., 2009; Lundén et al., 2009; Klein et al.,
189 2007; Karsunky et al., 2002; Person et al., 2003; Boztug et al., 2009). These genes also play a
190 role in the differentiation and function of neutrophils that are produced in the bone marrow.
191 SCN has been shown to cause severe periodontal tissue destruction in addition to systemic
192 infection, while aggressive periodontitis patients with mutations in *MMD2* are healthy but
193 have localized infections in the oral cavity. This study showed that neutrophil abnormalities
194 were important for the development of periodontal disease, because periodontal tissue was
195 destroyed even if the neutropenia was mild. Additionally, aggressive periodontitis with
196 *MMD2* mutation was considered to belong to the same spectrum of SCN due to a common
197 mechanism that leads to abnormal number and function of neutrophils.

198 At present, symptomatic treatment is given for aggressive periodontitis; however, it
199 does not fully recover the periodontal tissue. There are reports of SCN patients with absolute
200 neutrophil counts normalized by G-CSF who still have severe periodontitis (Putsep, 2002;
201 Carlsson et al., 2006). Therefore, the level of absolute neutrophil count normalized by
202 G-CSF is not enough to maintain normal oral health in these patients. A more detailed

203 examination of the immune response for aggressive periodontitis caused by *MMD2* mutation
204 may lead to the development of a new treatment alternative to not only aggressive
205 periodontitis caused by *MMD2* mutation but also to periodontitis in general.

206 MMD and *MMD2* are two members of the progesterin and adiponQ receptor family (Tang
207 et al., 2005). As its name suggests, MMD is involved in macrophage activation and may
208 increase the production of TNF- α and nitric oxide in lipopolysaccharide-stimulated
209 macrophages through ERK1/2 and Akt phosphorylation (Liu et al., 2012). A genome-wide
210 association study in patients with Crohn's disease (CD) identified *MMD2* as a CD-related
211 gene (Montero-Melendez, 2013). CD is an inflammatory disease due to abnormal immune
212 reaction to many commensal bacteria in genetically susceptible individuals. Thus, *MMD2*
213 gene may be involved in the immune response system to chronic bacterial infection.
214 Therefore, in presence of the *MMD2* mutation and harmful bacteria, diseases in the intestine
215 and the oral cavity are likely to develop.

216 Additionally, identification of *MMD2* may allow to differentiate between chronic and
217 aggressive periodontitis, as until today there is a controversy about whether chronic and
218 aggressive periodontitis should be classified or not as the same type of periodontitis. As a
219 conclusion, our study highlighted the influence of mild immune system defects on the onset
220 of aggressive periodontitis, which should be considered during the diagnosis of the disease.
221 Furthermore, the study of mild neutropenia and related diseases may attract the attention of
222 the medical field other than periodontology and lead to the development of new diagnostic
223 and therapeutic methods.

224 **Materials and Methods**

225 **Study family**

226 This study was approved by the Human Subjects Committees of Hiroshima University.
227 Written informed consent was obtained from all subjects. All affected individuals were
228 diagnosed with aggressive periodontitis according to periodontal and X-ray examinations.
229 Blood was collected from the four affected and the four unaffected individuals in this family
230 for genetic analyses. Also, blood and bone marrow samples were collected from III-2 and
231 III-4 patients, and FACS analysis, chemotaxis assay, and CT imaging were performed.

232 **Differentiation of human CD34⁺ HSPCs into granulocytes**

233 Cells were purified from the bone marrow and peripheral blood. Mononuclear cells,
234 previously separated by Ficoll-Hypaque density centrifugation (GE Healthcare Biosciences,
235 Uppsala, Sweden), were stained with a variety of antibodies and subjected to flow cytometry.
236 CD34⁺ HSPCs were isolated from patients' blood using the CD34 Microbeads Kit (Miltenyi
237 Biotec, Bergisch Gladbach, Germany). CD34⁺ HSPCs from healthy volunteers were
238 purchased from HemaCare (HemaCare, Northridge, CA, USA). Then, CD34⁺ HSPCs were
239 incubated in StemSpan SFEM II medium with StemSpan Myeloid Expansion Supplement
240 (Stem cell technologies, Vancouver, Canada) for 10 days. Further, harvested cells were
241 stained with anti-CD33 antibody (Bio Biosciences, Franklin Lakes, NJ, USA) and subjected
242 to flow cytometry analysis.

243 **Chemotaxis assay**

244 Neutrophils were suspended in RPMI1640 (Nakalai tesque, Kyoto, Japan) with
245 1000 mg/L glucose and penicillin/streptomycin. Chemotaxis was induced with fMLP
246 (100 nM) for 120 min at 37 °C and measured by the Boyden chamber method with a 96-well
247 micro-chemotaxis chamber containing a 3- μ m pore-sized filter (CELL BIOLABS, INC., San
248 Diego, CA, USA).

249 **Linkage analysis**

250 The samples used for linkage analysis were II-1, II-6, II-9, III-2, III-3, III-4, and III-5.
251 Genomic DNA (gDNA) was extracted from the venous blood of each individual according to
252 standard protocols. We used the Genome-Wide Human SNP Array 6.0 (Affymetrix, Santa
253 Clara, CA, USA) for genotyping single nucleotide polymorphisms (SNPs), and linkage
254 analysis was performed by Allegro software, assuming dominant inheritance.

255 **Exome sequencing and variant filtering**

256 The gDNA libraries were prepared using a SeqCap EZ Human Exome Library v2.0
257 (Roche, Basel, Switzerland). Sequencing was performed with 100-bp paired-end reads by the
258 HiSeq2000 sequencer (Illumina, San Diego, CA, USA). We used Burrows-Wheeler Aligner
259 for alignment and mapping, and SAMtools and Picard for SAM/BAM. Exome sequencing
260 was performed using the GATK and SAMtools for variant calls and Annovar for annotation.
261 Functional predictions of amino acid changes were performed using PolyPhen-2, Mutation
262 Taster, SIFT, and the Combined Annotation Dependent Depletion (CADD). Control exome
263 sequences were obtained from Japanese patients undergoing exome sequencing analysis for
264 other diseases. All reported genomic coordinates were in GRCh37/hg19. The identified
265 mutation was confirmed by standard polymerase chain reaction-based amplification, followed
266 by sequence analysis using Applied Biosystems 3130 DNA sequencer (Thermo Fisher
267 Scientific, Waltham, MA, USA).

268 **Double-staining procedures for immunofluorescence**

269 The primary antibodies used in this study were anti-MMD2 (CUSABIO, Houston, TX)
270 and anti-golgin-97 (Gene Tex, Irvine, CA, USA). Neutrophil-like HL-60 cells (1.0×10^5
271 cells/well in chamber slides) were fixed in 4 % paraformaldehyde and permeabilized with
272 0.2 % Triton X-100. For immunofluorescence analysis, cells were assessed on cytospin
273 preparations. Slides were incubated with anti-MMD2 and golgin-97 antibodies at 4 °C

274 overnight. MMD2 and golgin-97 proteins were detected after incubation with Alexa
275 Fluor-594 rabbit anti-donkey IgG and Alexa Fluor-488 mouse anti-donkey IgG secondary
276 antibodies, respectively. Nuclei were stained with 4,6-diamidino-2-phenylindole (DAPI).
277 Fluorescence signals were detected with Olympus Fluoview FV1000 laser scanning confocal
278 microscope (Olympus, Tokyo, Japan).

279 **Generation of mouse model using Platinum TALEN gene editing**

280 Mice carrying the *Mmd2* A117V variant were generated using the TALEN gene editing
281 tool. The TALEN pair that showed a high targeting efficiency and low off-target effects was
282 used for *in vitro* transcription by using the MEGAscript T7 Transcription Kit (Thermo Fisher
283 Scientific, Yokohama, JAPAN). TALEN mRNAs were combined with the ssODN construct
284 and injected into pronuclei of C57BL/6 single cell mouse embryos. We then backcrossed
285 *Mmd2*^{A117V/A117V} and *Mmd2*^{-/-} mice with C57BL/6 mice for eight generations.

286 **Ligature-induced periodontitis**

287 Periodontal inflammation and bone loss in a ligature-induced periodontitis model was
288 initiated by the abundant local accumulation of bacteria on ligated molar teeth. To this end, a
289 5-0 silk ligature was tied around the maxillary second molar in 8-week-old male mice. The
290 distance between cement-enamel junction and alveolar bone crest was examined at 7 days
291 after placement of the ligatures.

292 **Colony formation assays**

293 Mouse bone marrow cells (2.5×10^4) suspended in methylcellulose semisolid medium
294 (Methocult M3231) (Stem Cell Technologies) were plated in 35-mm culture dishes in the
295 presence of 0.5 % FBS, 10 ng/mL mouse G-CSF, 10 ng/mL mouse GM-CSF, 10 ng/mL
296 mouse M-CSF, and 10 ng/mL mouse IL-3 (BioLegend, San Diego, CA, USA).

297

298

299 **Statistical analysis**

300 The results are expressed as the mean \pm standard deviation. Statistical differences
301 between the mean values of the control and experimental groups were analyzed by using
302 Student's t test. Those p-values ≤ 0.05 were considered statistically significant.

303 **Acknowledgments**

304 We thank the families involved in this research. We would like to thank Editage (www.
305 editage.jp) for English language editing.

306 **Author contributions**

307 Noriyoshi Mizuno, Hiroyuki Morino, and Keichiro Mihara: study concept and design,
308 acquisition, analysis, and interpretation of data, manuscript preparation and revision;
309 Tomoyuki Iwata: statistical analysis; Yoshinori Ohno, Shinji Matsuda, Kazuhisa Ouhara,
310 Mikihiro Kajiya, Kyoko Suzuki-Takedachi: data acquisition and patient evaluation; Yusuke
311 Sotomaru, Katsuhiko Takeda, Shinya Sasaki, and Ai Okanobu: data acquisition and
312 manuscript revision; Tetsushi Sakuma and Takashi Yamamoto: data acquisition; Yukiko
313 Matsuda, Ryouzuke Ohsawa, and Tsuyoshi Fujita: data analysis; Hideki Shiba, Hideshi
314 Kawakami, Hidemi Kurihara: study concept and design, and manuscript revision.

315 **Competing Interests**

316 The authors have no conflicts of interest to declare.

317 **Disclosure**

318 The authors report no disclosures regarding this manuscript.

319 **Study Funding**

320 This work was supported in part by the Japan Society for the Promotion of Science
321 KAKENHI Grant-in-Aid for Scientific Research (No. 15K11388 and 18H0297800), a GSK
322 Japan Research Grant from Glaxo Smith Kline, and the Takeda Science Foundation.

323 **References**

- 324 1. Nishimura, F. et al. (1990) A family study of a mother and daughter with increased
325 susceptibility to early-onset periodontitis: microbiological, immunological, host
326 defensive, and genetic analyses. *Journal of Periodontology*. **61**:755–762.
327 DOI:10.1902/jop.1990.61.12.755
- 328 2. Trevilatto, P. C. et al. (2002) Clinical, genetic and microbiological findings in a
329 Brazilian family with aggressive periodontitis. *Journal of Clinical Periodontology*
330 **29**:233–239. DOI: 10.1034/j.1600-051x.2002.290309.x
- 331 3. Llorente, M. A., Griffiths, G. S. (2006) Periodontal status among relatives of
332 aggressive periodontitis patients and reliability of family history report. *Journal of*
333 *Clinical Periodontology* **33**:121–125. DOI: 10.1111/j.1600-051X.2005.00887.x
- 334 4. Albandar, J. M., Tinoco, E. M. (2002) Global epidemiology of periodontal diseases in
335 children and young persons. *Periodontology 2000* **29**:153–176.
- 336 5. Van Dyke, T. E., Horoszewicz, H. U., Cianciola, L. J., Genco, R. J. (1980) Neutrophil
337 chemotaxis dysfunction in human periodontitis. *Infection and Immunity*. **27**:124–132.
- 338 6. Van Dyke, T. E., Schweinebraten, M., Cianciola, L. J., Offenbacher, S., Genco, R. J.
339 (1985) Neutrophil chemotaxis in families with localized juvenile periodontitis.
340 *Journal of Periodontology Research* **20**:503–514. DOI:
341 10.1111/j.1600-0765.1985.tb00834.x
- 342 7. Shapira, L., Borinski, R., Sela, M. N., Soskolne, A. (1991) Superoxide formation and
343 chemiluminescence of peripheral polymorphonuclear leukocytes in rapidly
344 progressive periodontitis patients. *Journal of Clinical Periodontology* **18**:44–48. DOI:
345 10.1111/j.1600-051x.1991.tb01118.x
- 346 8. Ueda, T., et al. (2001) Hematopoietic capability of CD34+ cord blood cells: a
347 comparison with CD34+ adult bone marrow cells. *International Journal of*

- 348 *Hematology* **73**:457–462. DOI: 10.1007/BF02994007
- 349 9. Jin, T., et al. (2012) Identification of the topology and functional domains of PAQR10.
350 *The Biochemical Journal* **443**:643–653. DOI: 10.1042/BJ20112105
- 351 10. Tang, Y. T., et al. (2005) PAQR proteins: a novel membrane receptor family defined
352 by an ancient 7-transmembrane pass motif. *Journal of Molecular Evolution* **61**:372–
353 380. DOI: 10.1007/s00239-004-0375-2
- 354 11. Abe, T., Hajishengallis, G. (2013) Optimization of the ligature-induced periodontitis
355 model in mice. *Journal of Immunological Methods* **394**:49–54. DOI:
356 10.1016/j.jim.2013.05.002
- 357 12. Lanciotti, M., et al. (2009) Severe congenital neutropenia: a negative synergistic
358 effect of multiple mutations of ELANE (ELA2) gene. *British Journal of Haematology*
359 **146**:578–580. DOI: 10.1111/j.1365-2141.2009.07787.x
- 360 13. Lundén, L., et al. (2009) Double de novo mutations of ELANE (ELA2) in a patient
361 with severe congenital neutropenia requiring high-dose G-CSF therapy. *British*
362 *Journal of Haematology* **147**:587–590. DOI: 10.1111/j.1365-2141.2009.07866.x
- 363 14. Klein, C., et al. (2007) HAX1 deficiency causes autosomal recessive severe
364 congenital neutropenia (Kostmann disease). *Nature Genetics* **39**:86–92. DOI:
365 10.1038/ng1940
- 366 15. Karsunky, H., et al. (2002) Inflammatory reactions and severe neutropenia in mice
367 lacking the transcriptional repressor Gfi1. *Nature Genetics* **30**:295–300. DOI:
368 10.1038/ng831
- 369 16. Person, R. E., et al. (2003) Mutations in proto-oncogene GFI1 cause human
370 neutropenia and target ELA2. *Nature Genetics* **34**:308–312. DOI: 10.1038/ng1170
- 371 17. Boztug, K., et al. (2009) A syndrome with congenital neutropenia and mutations in
372 G6PC3. *The New England Journal of Medicine* **360**:32–43. DOI:

- 373 10.1056/NEJMoa0805051
- 374 18. Putsep, K., Carlsson, G., Boman, H. G., Andersson, M. (2002) Deficiency of
375 antibacterial peptides in patients with morbus Kostmann: an observation study. *Lancet*
376 **360**:1144–1149. DOI: 10.1016/S0140-6736(02)11201-3
- 377 19. Carlsson, G., et al. (2006) Periodontal disease in patients from the original Kostmann
378 family with severe congenital neutropenia. *Journal of Periodontology* **77**:744–751.
379 DOI: 10.1902/jop.2006.050191
- 380 20. Tang, Y. T., et al. (2005) PAQR proteins: a novel membrane receptor family defined
381 by an ancient 7-transmembrane pass motif. *Journal of Molecular Evolution* **61**:372–
382 380. DOI: 10.1007/s00239-004-0375-2
- 383 21. Liu, Q., et al. (2012) Monocyte to macrophage differentiation-associated (MMD)
384 positively regulates ERK and Akt activation and TNF-alpha and NO production in
385 macrophages. *Molecular Biology Reports* **39**:5643–5650. DOI:
386 10.1007/s11033-011-1370-5
- 387 22. Montero-Melendez, T., Llor, X., Garcia-Planella, E., Perretti, M., Suarez, A. (2013)
388 Identification of novel predictor classifiers for inflammatory bowel disease by gene
389 expression profiling. *PLoS One* **8**:e76235. DOI: 10.1371/journal.pone.0076235
- 390

391 **Figure legends**

392 **Fig. 1. Characteristic findings in patients with *MMD2* mutation.** Panel A shows the
393 family tree chart. Arrows indicate the proband. Filled and open symbols represent affected
394 and unaffected individuals, respectively. Genotypes of the variant c.347C>T are shown under
395 the number of samples. Asterisks indicate the patients whose samples were used for exome
396 sequencing. Panel B shows computed tomography images of age-matched healthy subjects
397 (upper), a 45-year-old III-2 patient (middle), and a 40-year-old age III-4 patient (lower).

398 **Fig. 2. Cellular analysis in patients with *MMD2* mutation.** Panel A indicates the induced
399 number of CD33⁺ cells from CD34⁺ HSPCs of the patients III-2 and III-4, which decreased in
400 number compared to that of healthy subjects. T bars indicate standard deviations. Panel B
401 shows flow cytometric analysis of HSPCs from healthy subjects and (III-2 and III-4) patients
402 after gating on CD45⁺ cells and by using anti-CD33 and anti-CD34 antibodies. Panel C
403 shows that neutrophil chemotaxis, induced by fMLP (100 nM, 4 h), in the patients III-2 and
404 III-4 was decreased compared with that of healthy subjects (H1, H2). The results are
405 expressed as the mean \pm standard deviation. Those p-values \leq 0.05 were considered
406 statistically significant by using Student's t test.

407 **Fig. 3. Identification of the *MMD2* mutation.** Panels A and B show linkage analysis of the
408 studied family. Arrows indicate the position of *MMD2* gene. Panel C shows Sanger
409 sequencing of *MMD2* gene exon 4 with or without the mutation. Panel D specifies the amino
410 acid sequences that were completely conserved among vertebrates. Panel E revealed the
411 intracellular localization of MMD2 protein in neutrophil-like HL-60 cells. The Golgi was
412 labeled with Golgin-97 (green); meanwhile, nuclei were stained blue with DAPI. Cells were
413 observed under a confocal fluorescence microscope. Panel F shows the structure of seven TM

414 domains encoded by *MMD2*. The star indicates the position of the identified mutation in
415 TM3.

416 **Fig. 4. Generation of *Mmd2* A117V knock-in mice using Platinum TALEN.** Panel A
417 shows the genomic structure of *Mmd2*, indicating the two binding sites of the TALENs.
418 TALEN pairs were designed to bind the exon 4 in the *Mmd2* gene. Panel B specifies the
419 ssODN sequence. Panel C indicates the KI allele. Panel D shows the sequence information of
420 *Mmd2* mutant alleles, specifically, sequences obtained from mutant mice, which were
421 generated by microinjection of TALEN mRNA. The DNA sequences that were used for
422 designing the TALENs are highlighted in red. Nucleotide mutations and indels are shown.
423 Panel E illustrates the Sanger sequencing performed to confirm the *Mmd2* variant. The
424 reference nucleotide C was substituted with variant nucleotide T in the mutant sample. A 7 bp
425 deletion resulted in frameshifting and thus in truncated proteins.

426 **Fig. 5. Periodontitis induction in *Mmd2*^{A117V/A117V} and *Mmd2*^{-/-} mice.** Panel A shows
427 representative photographs of the maxilla of treated and non-treated mice. Scale bar = 1 mm.
428 Panel B displays schematics of periodontal bone loss measurements. The distance between
429 cement-enamel junction and alveolar bone crest at the distal facial side of the first molar, at
430 the mesial and distal facial side of the second molar, and at the mesial facial side of the third
431 molar were measured (+/+, n = 19; A117V/+, n = 20; A117V/A117V, n = 8; -/-, n = 8). The
432 results are expressed as the mean ± standard deviation. Those p-values ≤ 0.05 were
433 considered statistically significant by using Student's t test.

434 **Fig. 6. Cellular analysis of *Mmd2*^{A117V/A117V} and *Mmd2*^{-/-} mice.** Panel A shows ratios of
435 granulocytes, lymphocytes, and monocytes in white blood cells (n = 5). Panel B indicates
436 colony formation from bone marrow cells in response to cytokines (n = 6). The results are the

437 average of at least six independent experiments performed with each individual mouse. T
438 bars indicate standard deviations. Panel C reveals that neutrophil chemotaxis, induced by
439 fMLP (100 nM, 4 h), in *MMD2*^{A117V/A117V} and *MMD2*^{-/-} mice was decreased compared with
440 that of *MMD2*^{+/+} mice (n = 5). The results are expressed as the mean ± standard deviation.
441 Those p-values ≤ 0.05 were considered statistically significant by using Student's t test.
442

443 **Additional Files**

444 **Figure 2-source data 1.** Source data for Figure 2A.

445 **Figure 2-source data 2.** Source data for Figure 2C.

446 **Figure 5-source data 1.** Source data for Figure 5B.

447 **Figure 6-source data 1.** Source data for Figure 6A.

448 **Figure 6-source data 2.** Source data for Figure 6B.

449 **Figure 6-source data 3.** Source data for Figure 6C.

450 **Table 4 - source data 1.** Source data for Table 4.

451 **Supplementary Table 1.**

452 **Supplementary Table 2.**

453 **Supplementary Table 3.**


454 **Supplementary Table 4.**

455


456 **Figures**

457

A




B



458

459 Fig. 1.


460



461

462 Fig. 2.

463



464

465 Fig. 3.

466






Fig. 4.



504

505 Fig. 5.

506



507

508 Fig. 6.

509

510

511 **Tables**

Table S1. Data of complete blood count (Patients).

| | III-2 | III-3 | III-4 | Reference Range |
|-----------------------|-------|-------|-------|-----------------|
| RBC (/nl) | 4,960 | 4,870 | 4,840 | 4,200-5,600 |
| Hemoglobin (g/dl) | 15.3 | 14.6 | 14.1 | 12.5-17.0 |
| PLT (nl) | 202 | 248 | 208 | 150-350 |
| WBC (/nl) | 3,120 | 2,500 | 3,080 | 4,000-9,000 |
| Neutrophil (%) | 31.1 | 35.3 | 31.3 | 43.0-71.0 |
| Lymphocyte (%) | 55.9 | 53.7 | 57.6 | 30.0-41.0 |
| Monocyte (%) | 5.8 | 8.0 | 6.6 | 3.0-6.0 |
| Eosinophil (%) | 5.9 | 2.0 | 3.2 | 2.0-6.0 |
| Basophil (%) | 1.3 | 1.0 | 1.3 | 0.0-2.0 |
| Neutrophil (μ l) | 970 | 883 | 964 | 1,720-6,390 |

512

513

| Table S2. Summary of exome sequencing. | | | |
|---|---------------|---------------|---------------|
| Sample | III-2 | III-3 | III-4 |
| <Sequence Info> | | | |
| Total reads (bp) | 7,835,611,079 | 7,647,632,797 | 7,246,927,551 |
| Mean depth | 73.9 | 72.1 | 68.3 |
| >10 reads (%) | 61.7 | 61.3 | 61.5 |
| <Variant> | | | |
| Total | 91,643 | 90,396 | 91,052 |
| -dbSNP/TGP | 13,818 | 13,516 | 13,128 |
| Exon/splice | 2,148 | 2,122 | 1,958 |
| AA change | 1,743 | 1,725 | 1,589 |
| Het | 1,547 | 1,534 | 1,392 |
| Common | | 282 | |
| Disease specific | | 7 | |
| Pathogenic | | 3 | |
| Linkage | | 1 | |

514

515

Table S3. Candidate variants.


| Variant | Gene | PolyPhen-2 | Mutation Taster | SIFT | CADD | Segregation | Linkage |
|---------------------|---------------------|-------------------|-----------------|------------|-------|-------------|---------|
| Chr1:236144983C>T | <i>NID1</i> | PROBABLY DAMAGING | DISEASE CAUSING | DAMAGING | 27.7 | No | No |
| Chr3:195506098T>G | <i>MUC4</i> | BENIGN | POLYMORPHISM | NOT SCORED | 5.977 | No | No |
| Chr3:195508545->G | <i>MUC4</i> | N.A. | DISEASE CAUSING | DAMAGING | 24.3 | No | No |
| Chr6:30954525G>A | <i>MUC21</i> | BENIGN | POLYMORPHISM | TOLERATED | 0.007 | No | No |
| Chr6:30954526C>T | <i>MUC21</i> | BENIGN | POLYMORPHISM | TOLERATED | 5.61 | No | No |
| Chr7:4955653G>A | <i>MMD2</i> | PROBABLY DAMAGING | DISEASE CAUSING | DAMAGING | 28.9 | Yes | Yes |
| Chr12:90908G>A | <i>LOC100288778</i> | BENIGN | N.A. | TOLERATED | 14.68 | No | No |
| N.A.: not available | | | | | | | |

516
517

| Table S4. Data of complete blood count (mouse). | | | |
|--|---------------------|-----------------------------|---------------------|
| | MMD2 ^{+/+} | MMD2 ^{A117V/A117V} | MMD2 ^{-/-} |
| RBC ($\times 10^4/\mu\text{l}$) | 908.0 \pm 24.8 | 884.8 \pm 99.5 | 901.3 \pm 48.0 |
| Hemoglobin (g/dl) | 14.0 \pm 0.9 | 14.6 \pm 1.8 | 14.0 \pm 0.9 |
| PLT (/nl) | 78.9 \pm 19.1 | 100.4 \pm 46.0 | 86.5 \pm 26.7 |
| WBC (/μl) | 2398 \pm 999 | 1738 \pm 316 | 1598 \pm 361 |

518


519 The results are expressed as the mean \pm standard deviation.

APedigree and *MMD2* genotype**B**


Healthy subject








Patient (III-2)



Patient (III-4)




A**B****C**



C

MMD2 exon 4 sequence




D

Protein sequence conservation

| | | | | | | | | | | | | | | | | |
|--------------------|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Human | D | R | M | V | I | Y | F | F | I | A | A | S | Y | A | P | W |
| Rhesus | D | R | M | V | I | Y | F | F | I | A | A | S | Y | A | P | W |
| Mouse | D | R | M | V | I | Y | F | F | I | A | A | S | Y | A | P | W |
| Dog | D | R | M | V | I | Y | F | F | I | A | A | S | Y | A | P | W |
| Elephant | D | R | M | V | I | Y | F | F | I | A | A | S | Y | A | P | W |
| Opossum | D | R | M | V | I | Y | F | F | I | A | A | S | Y | A | P | W |
| Chicken | D | R | M | V | I | Y | F | F | I | A | A | S | Y | A | P | W |
| Xenopus tropicalis | D | R | M | V | I | Y | F | F | I | A | A | S | Y | A | P | W |
| Zebrafish | D | R | M | V | I | Y | F | F | I | A | A | S | Y | A | P | W |


E


The intracellular localization of *MMD2*



F

Structure of seven TM proteins encoded by *MMD2*





B

ssODN sequence (5'→3', 40-mer arm, total 87-mer)

ctgcacatgatcgacaggatggtgatcactactcttcattgTcgctAGctatgctccttggtagtgccagtgccccaccacccccactg

T: target base substitution


TAG: base substitution for RFLP




C



| | | | | | | | | | | | | | |
|-----------|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|
| KI allele | atg | gtg | atc | tac | ttc | ttc | att | gTc | gcT | AGc | tat | gct | cct |
| | M | V | I | Y | F | F | I | V | A | S | Y | A | P |

D

| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
|----------------------------------|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| WT | a | t | g | g | t | g | a | t | c | t | a | c | t | t | c | a | t | t | g | c | c | t | t | a | t | t | g | c | c | t | t | g | t | g | a | t | g | c | c | a | g | t | g | |
| 5 bp deletion | a | t | g | g | t | g | a | t | c | t | a | c | t | t | c | a | t | t | g | c | c | t | t | a | t | t | g | c | c | t | t | g | t | g | a | t | g | c | c | a | g | t | g | |
| 6 bp deletion | a | t | g | g | t | g | a | t | c | t | a | c | t | t | c | a | t | t | g | c | c | t | t | a | t | t | g | c | c | t | t | g | t | g | a | t | g | c | c | a | g | t | g | |
| 7 bp deletion | a | t | g | g | t | g | a | t | c | t | a | c | t | t | c | a | t | t | g | c | - | - | - | a | t | t | g | c | c | t | t | g | t | g | a | t | g | c | c | a | g | t | g | |
| 11 bp deletion | a | t | g | g | t | g | a | t | c | t | a | c | t | t | c | a | t | t | g | c | - | - | - | - | a | t | t | g | c | c | t | t | g | t | g | a | t | g | c | c | a | g | t | g |
| 3 bp deletion+ 6 bp insertion | a | t | g | g | t | g | a | t | c | t | a | c | t | t | c | a | t | t | g | c | g | c | t | a | c | t | g | c | c | t | t | g | t | g | a | t | g | c | c | a | g | t | g | |
| A117V | a | t | g | g | t | g | a | t | c | t | a | c | t | t | c | a | t | t | g | c | t | g | c | t | a | t | t | g | c | c | t | t | g | t | g | a | t | g | c | c | a | g | t | g |



A**B**

A**B****C**